AS is a chronic inflammatory disease belonging to the group of spondyloarthritides, involving primarily the sacroiliac joints and the axial skeleton, resulting in chronic back pain and stiffness. Diagnosis can be difficult, and left untreated AS can result in structural damage and disability. The key treatment goals for AS include improving signs and symptoms of the disease, improving physical function, preventing disability, and slowing or preventing structural damage. TNF-α inhibitors have demonstrated efficacy in reducing disease activity in AS, and all approved agents in this class are perceived as highly effective options for patients who require more potent therapies beyond first-line NSAIDs. The IL-17 inhibitor Cosentyx offers an alternative mechanism of action as the only approved non-TNF biologic therapy for AS.t


Related Reports

Axial Spondyloarthritis - Access & Reimbursement - Detailed, Expanded Analysis: Axial Spondyloarthritis (ankylosing Spondylitis And Nonradiographic Axial Spondyloarthritis) - US

The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: the tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen’s Enbrel, AbbVie’s...

View Details

Axial Spondyloarthritis - Unmet Need - Detailed, Expanded Analysis: Ankylosing Spondylitis (US & EU)

In the last 15 years, TNF-α inhibitors (AbbVie’s Humira, Amgen / Pfizer’s Enbrel, Janssen’s Remicade and Simponi, UCB’s Cimz...

View Details

Axial Spondyloarthritis - Current Treatment - Detailed, Expanded Analysis : Treatment Algorithms : Claims Data Analysis : Ankylosing Spondylitis (US)

MARKET OUTLOOKAnkylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and the axi...

View Details